{"id":553655,"date":"2021-07-20T16:28:01","date_gmt":"2021-07-20T16:28:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=553655"},"modified":"2021-07-20T16:28:01","modified_gmt":"2021-07-20T16:28:01","slug":"fibrodysplasia-ossificans-progressiva-pipeline-drugs-and-companies-insight-report-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/fibrodysplasia-ossificans-progressiva-pipeline-drugs-and-companies-insight-report-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments_553655.html","title":{"rendered":"Fibrodysplasia Ossificans Progressiva Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1626781367.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Fibrodysplasia Ossificans Progressiva Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments\" src=\"https:\/\/www.abnewswire.com\/uploads\/1626781367.png\" alt=\"Fibrodysplasia Ossificans Progressiva Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s \u201cFibrodysplasia Ossificans Progressiva Pipeline Insight\u201d report provides comprehensive insights about key companies and pipeline drugs in the Fibrodysplasia Ossificans Progressiva pipeline landscapes. It comprises Fibrodysplasia Ossificans Progressiva pipeline drug profiles, including clinical and non-clinical stage products. <\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight&rsquo;s <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/fibrodysplasia-ossificans-progressiva-fop-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">&ldquo;<strong>Fibrodysplasia Ossificans Progressiva Pipeline Insight&rdquo;<\/strong><\/a> report provides comprehensive insights about key companies&nbsp;and pipeline drugs in the Fibrodysplasia Ossificans Progressiva pipeline landscapes. It comprises Fibrodysplasia Ossificans Progressiva pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Fibrodysplasia Ossificans Progressiva therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Fibrodysplasia Ossificans Progressiva pipeline products.&nbsp; &nbsp; &nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/47e4cd1bbe5f6b48eda1aaa80339a9b8.jpg\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Some of the key takeaways of the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/fibrodysplasia-ossificans-progressiva-fop-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Fibrodysplasia Ossificans Progressiva Pipeline Report<\/a><\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as<\/span><span data-mce-mark=\"1\"> Ipsen, Keros Therapeutics, Regeneron Pharmaceuticals, BioCryst,<\/span><span data-mce-mark=\"1\"> etc., are developing therapies for the treatment of Fibrodysplasia Ossificans Progressiva.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Emerging therapies such as <\/span><span data-mce-mark=\"1\">Palovarotene and&nbsp; BLU-782, KER-047, Garetosmab (REGN2477), BCX9250,&nbsp; <\/span><span data-mce-mark=\"1\">are expected to have a significant impact on the <\/span><span data-mce-mark=\"1\">&nbsp;Fibrodysplasia Ossificans Progressiva <\/span><span data-mce-mark=\"1\">market in the coming years.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Garetosmab (REGN2477)<\/span><span data-mce-mark=\"1\"> is an intravenously administered product in Phase II clinical trials by <\/span><span data-mce-mark=\"1\">Regeneron Pharmaceuticals <\/span><span data-mce-mark=\"1\">for <\/span><span data-mce-mark=\"1\">Fibrodysplasia Ossificans Progressiva<\/span><span data-mce-mark=\"1\">.&nbsp;<\/span><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Get an overview of pipeline landscape @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/fibrodysplasia-ossificans-progressiva-fop-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Fibrodysplasia Ossificans Progressiva Clinical Trials Analysis &nbsp;<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">Fibrodysplasia ossificans progressiva (FOP) is a disorder in which skeletal muscle and connective tissue, such as tendons and ligaments, are gradually replaced by bone (ossified). This condition leads to bone formation outside the skeleton (extra-skeletal or heterotopic bone) that restricts movement. People with FOP are born with abnormal big toes (hallux valgus) which can be helpful in making the diagnosis. These flare-ups last for several days to months and often result in permanent bone growth in the injured area.<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Fibrodysplasia Ossificans Progressiva Emerging Drugs<\/strong><\/p>\n<ol style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Palovarotene and&nbsp; BLU-782 by Ipsen<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">KER-047 by Keros Therapeutics<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Garetosmab (REGN2477) by Regeneron Pharmaceuticals<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">BCX9250 by BioCryst<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">And others.<\/span><\/p>\n<\/li>\n<\/ol>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\"><strong>Scope of Fibrodysplasia Ossificans Progressiva Pipeline Drug Insight&nbsp;<\/strong>&nbsp;&nbsp;&nbsp;<\/span><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Coverage: <\/span><span data-mce-mark=\"1\">Global&nbsp;<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Major Players:<\/span><span data-mce-mark=\"1\"> Ipsen, Keros Therapeutics, Regeneron Pharmaceuticals, BioCryst, and others.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Pipeline Therapies:<\/span><span data-mce-mark=\"1\"> Palovarotene and&nbsp; BLU-782, KER-047, Garetosmab (REGN2477), BCX9250,&nbsp; and others.<\/span><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Contents<\/strong><\/p>\n<div style=\"text-align: justify;\" dir=\"ltr\" align=\"left\">\n<table>\n<colgroup>\n<col width=\"22\" \/>\n<col width=\"386\" \/><\/colgroup>\n<tbody>\n<tr>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">1<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Fibrodysplasia Ossificans Progressiva Report Introduction<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">2<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Fibrodysplasia Ossificans Progressiva Executive Summary<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">3<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Fibrodysplasia Ossificans Progressiva Overview<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">4<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Fibrodysplasia Ossificans Progressiva- Analytical Perspective In-depth Commercial Assessment<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">5<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Fibrodysplasia Ossificans Progressiva Pipeline Therapeutics<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">6<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Fibrodysplasia Ossificans Progressiva Late Stage Products (Phase II\/III)<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">7<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Fibrodysplasia Ossificans Progressiva Mid Stage Products (Phase II)<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">8<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Fibrodysplasia Ossificans Progressiva Early Stage Products (Phase I)<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">9<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Fibrodysplasia Ossificans Progressiva Preclinical Stage Products<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">10<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Fibrodysplasia Ossificans Progressiva Therapeutics Assessment<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">11<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Fibrodysplasia Ossificans Progressiva Inactive Products<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">12<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Company-University Collaborations (Licensing\/Partnering) Analysis<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">13<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Fibrodysplasia Ossificans Progressiva Key Companies<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">14<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Fibrodysplasia Ossificans Progressiva Key Products<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">15<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Fibrodysplasia Ossificans Progressiva Unmet Needs<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">16&nbsp;<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Fibrodysplasia Ossificans Progressiva Market Drivers and Barriers<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">17<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Fibrodysplasia Ossificans Progressiva Future Perspectives and Conclusion<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">18<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Fibrodysplasia Ossificans Progressiva Analyst Views<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">19<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Appendix<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">20<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">About DelveInsight<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Get a customized pipeline report @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/fibrodysplasia-ossificans-progressiva-fop-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Fibrodysplasia Ossificans Progressiva Drugs Pipeline Report&nbsp;&nbsp;<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Related Reports:<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Fibrodysplasia Ossificans Progressiva Market&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">DelveInsight&#8217;s Fibrodysplasia Ossificans Progressiva &#8211; Market Insights, Epidemiology, and Market Forecast-2030 report deliver an in-depth understanding of the Fibrodysplasia Ossificans Progressiva, historical and forecasted epidemiology as well as the Fibrodysplasia Ossificans Progressiva market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Fibrodysplasia Ossificans Progressiva Epidemiology&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight&#8217;s &#8216; Fibrodysplasia Ossificans Progressiva- Epidemiology Forecast to 2030&#8217; report delivers an in-depth understanding of the disease, historical and forecasted&nbsp; Fibrodysplasia Ossificans Progressiva epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56431.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Kritika Rehani<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=fibrodysplasia-ossificans-progressiva-pipeline-drugs-and-companies-insight-report-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=fibrodysplasia-ossificans-progressiva-pipeline-drugs-and-companies-insight-report-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP DelveInsight\u2019s \u201cFibrodysplasia Ossificans Progressiva Pipeline Insight\u201d report provides comprehensive insights about key companies and pipeline drugs in the Fibrodysplasia Ossificans Progressiva pipeline landscapes. It comprises Fibrodysplasia Ossificans Progressiva pipeline drug profiles, including clinical and non-clinical stage &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/fibrodysplasia-ossificans-progressiva-pipeline-drugs-and-companies-insight-report-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments_553655.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-553655","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/553655","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=553655"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/553655\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=553655"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=553655"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=553655"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}